We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Image of Laura Elizabeth Lansdowne

Laura Elizabeth Lansdowne

Managing Editor

 at Technology Networks


As managing editor, Laura works with the associate editorial director to create, inform and maintain the overall editorial strategy for Technology Networks. She oversees the in-house editorial team and works directly with commissioned writers to produce content across the publication’s communities. After obtaining a first-class honors degree in biology, Laura worked as a quality assurance technologist before joining the Wellcome Sanger Institute and undertaking an additional qualification in clinical chemistry. In 2015, she left to pursue pharmaceutical and editorial-based roles, before joining Technology Networks in 2017.


Got a question for Laura Elizabeth Lansdowne?


Get in touch using the contact form linked here and we’ll get back to you shortly



Published Content
Total: 398
Opinionated Science Episode 39: The Science of Christmas Dinner content piece image
Podcast

Opinionated Science Episode 39: The Science of Christmas Dinner

In this bumper episode, the team review a series of studies from the last year that investigate Christmassy food. Could the future of Christmas dinner involve a cell culture roast, unnaturally smooth chocolate and fractal cauliflower?
Cancer Epigenetics content piece image
Infographic

Cancer Epigenetics

Today, there is growing evidence that in various diseases, including different types of cancer, there are underlying epigenetic mechanisms at play. Download this infographic to explore various epigenetic mechanisms in cancer.
New Non-Lethal Method To Study Scorpion Venom content piece image
News

New Non-Lethal Method To Study Scorpion Venom

Researchers have discovered a non-lethal way to study scorpion venom genes by triggering the emptying of the animal’s venom glands using electrostimulation. The study was published in PLOS ONE.
Team Reverses the Clinical Signs of Alzheimer’s Disease in Mice content piece image
Article

Team Reverses the Clinical Signs of Alzheimer’s Disease in Mice

In a study published in Genome Medicine, Dr. Patrick Aloy, head of the structural bioinformatics and network biology laboratory at IRB Barcelona and colleagues report that they have successfully reversed the clinical signs of Alzheimer's disease in mice by repurposing four existing drugs that are currently approved to treat high blood pressure and inflammation.
Identifying Novel Drug Targets for Neurodegeneration content piece image
Article

Identifying Novel Drug Targets for Neurodegeneration

During this year’s ELRIG Drug Discovery Meeting, Prof. Paul Brennan from the University of Oxford, discussed recent progress to develop drug compounds against novel targets in neuroinflammatory and sub-cellular organelle dysfunction pathways.
Opinionated Science Episode 37: Finding Answers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Mesothelioma content piece image
Podcast

Opinionated Science Episode 37: Finding Answers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Mesothelioma

In this podcast, the team look at two overlooked diseases. Malignant mesothelioma was known to be caused by the construction material asbestos decades before it was banned, while ME/CFS remains poorly understood by science. Two new developments could bring and clarity and a route to better treatment for these conditions.
The Role of Neuropilin-1 in SARS-CoV-2 Infection content piece image
Article

The Role of Neuropilin-1 in SARS-CoV-2 Infection

Dr. Maria Anastasina from the University of Helsinki and colleagues have been investigating the involvement of neuropilin-1 in SARS-CoV-2 cell entry and infectivity. Technology Networks had the pleasure of speaking with Anastasina to learn more about this work.
Reconnecting at ELRIG Drug Discovery 2021 content piece image
Article

Reconnecting at ELRIG Drug Discovery 2021

Technology Networks is delighted to be reporting – in person – from The European Laboratory Research & Innovation Group (ELRIG)'s Drug Discovery 2021 meeting. In this article, we explore the key themes discussed in the meeting's opening address.
Uncovering Key Interactions Between Cancer-Driving Proteins  content piece image
Article

Uncovering Key Interactions Between Cancer-Driving Proteins

Research conducted as part of the Cancer Cell Map Initiative (CCMI), has revealed interactions between cancer-driving proteins, that were unknown, until now. Findings were published in three separate papers in Science.
Large-Scale Bioproduction of Adherent Cells To Support Advanced Therapy Workflows content piece image
Industry Insight

Large-Scale Bioproduction of Adherent Cells To Support Advanced Therapy Workflows

In recent years, a number of new cell and gene therapies have been developed to treat a variety of indications, including cancer and inherited retinal dystrophies. While these therapies have proven to be beneficial to patients, their scalability and manufacturability are two enduring challenges. Technology Networks spoke to Tara St.Amand, PhD, MBA, director of business technology, bioprocess at Corning to learn more about the key challenges faced when scaling up the manufacturing of cell products.
Advertisement